This project will review the evidence for the medicinal use of cannabis and cannabinoid products for a number of key medical conditions.
Treatment and Intervention
Substance use amongst adolescents (those in the age group of 10-19) is an important public health issue in many countries of the region.
The monograph is an outcome of the Intergovernmental Committee on Drugs (IGCD) Fetal Alcohol Spectrum Disorder (FASD) Working Party.
Australian surveys of those with cannabis use disorder (CUD) reveal that general medical practitioners (GPs) are the preferred source of treatment as they are seen as trust worthy and confidential.
The Northern Territory prison population comprises 92% Indigenous Australians and 88% smokers. The NT prison-smoking ban creates a population-wide abstinence. We aim to extend this period of abstinence into the community.
The IDAT Program, established under the Drug and Alcohol Treatment Act 2007 of New South Wales, aims to “provide short-term care, with an involuntary supervised withdrawal component, to protect the health and safety of people with severe substance dependence who have experienced, or are at risk o
This randomised double-blind placebo-controlled study, led by St Vincent's Hospital Sydney, aims to examine the safety and efficacy of lisdexamfetamine in the treatment of adults with severe methamphetamine (MA) dependence.
NADA, under funding provided by the NSW Ministry for Health, is conducting a project to develop a set of treatment service specifications for the NSW specialist NGO drug and alcohol sector.
This project will conduct the first-ever outpatient RCT to test the efficacy, safety and cost-effectiveness of the pharmaceutical cannabinoid nabiximols (Sativex®) for treating cannabis dependence.